GURUFOCUS.COM » STOCK LIST » Financial Services » Capital Markets » Dominari Holdings Inc (NAS:DOMH) » Definitions » Float Percentage Of Total Shares Outstanding

DOMH (Dominari Holdings) Float Percentage Of Total Shares Outstanding : 83.03% (As of May. 06, 2025)


View and export this data going back to 1984. Start your Free Trial

What is Dominari Holdings Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Dominari Holdings's float shares is 12.16 Mil. Dominari Holdings's total shares outstanding is 14.64 Mil. Dominari Holdings's float percentage of total shares outstanding is 83.03%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Dominari Holdings's Insider Ownership is 27.81%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Dominari Holdings's Institutional Ownership is 4.30%.


Dominari Holdings Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Dominari Holdings's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=12.16/14.64
=83.03%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dominari Holdings Business Description

Industry
Traded in Other Exchanges
Address
725 5th Avenue, 22nd Floor, New York, NY, USA, 10020
Dominari Holdings Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The company's oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia.
Executives
Anthony Hayes director, officer: Chief Executive Officer 1796 SHADY LANE, COLUMBIA SC 29206
Kyle Michael Wool director 650 5TH AVE, 35TH FLOOR, NEW YORK NY 10019
Christopher Franklin Devall officer: Chief Operating Officer DOMINARI HOLDINGS INC., ONE ROCKEFELLER PLAZA, 11TH FLOOR, NEW YORK NY 10020
George Way officer: Chief Financial Officer C/O DOMINARI HOLDINGS INC., 725 5TH AVENUE 23RD FLOOR, NEW YORK NY 10022
Soo Yu director ONE ROCKEFELLER PLAZA, 11TH FLOOR, NEW YORK NY 10020
Tim S Ledwick director 10200 INNOVATION DRIVE, SUITE 300, MILWAUKEE WI 53226
Gregory James Blattner director ONE ROCKEFELLER PLAZA 11TH FLOOR, NEW YORK NY 10020
Paul Lemire director ONE ROCKEFELLER PLAZA, 11TH FLOOR, NEW YORK NY 10020
Robert Frederick Dudley director ONE ROCKEFELLER PLAZA, 11TH FLOOR, NEW YORK NY 10020
Zanden Robert J Vander director 913 HIGH KNOLL WAY, TRAVELERS REST SC 29690
Eric Weisblum director 285 GRAND AVENUE, ENGLEWOOD NJ 07631
Howard E Goldberg director 781 THIRD AVENUE, KING OF PRUSSIA PA 194061409
Frank Reiner officer: Interim CFO 6430 ROCKLEDGE DRIVE, SUITE 503, BETHESDA MD 20817
Jeffrey Ballabon director 6430 ROCKLEDGE DRIVE, BETHESDA NY 20817
Richard Cohen officer: Chief Financial Officer C/O DUNE ENERGY, INC., TWO SHELL PLAZA, 777 WALKER STREET, SUITE 2300, HOUSTON TX 77002